



Herpes Zoster Work Group Activity Update

ACIP Meeting
June 21, 2017

Edward Belongia, MD

ACIP Chair, Zoster Working Group

Center for Clinical Epidemiology & Population Health

Marshfield Clinic Research Institute

2017 Herpes Zoster Work Group

ACIP Members	Edward Belongia, MD (Chair)	
	Kelly Moore	
Ex Officio Members	Paula Agger, MD, MPH	FDA
	Jeffrey Cohen, MD	NIH
	Jeffrey Kelman, MD	CMS
Liaison Representatives	Jeffrey Duchin, MD	NACCHO
	Mary Pat Friedlander, MD	AAFP
	Adam Welch, PharmD	APhA
	William Schaffner, MD	NFID
	Kenneth Schmader, MD	AGS
	Sandra Fryhofer, MD	AMA/ACP
	Kathy Neuzil, MD, MPH	IDSA
	Mark Netoskie, MD, MBA	AHIP
	Lynn Bahta, RN, PHN	AIM

Invited Consultants
Robin Avery, MD
Al Benson, MD
Paul Cieslak, MD
Jeffrey Curtis, MD, MPH
Samuel Katz, MD
Vicki Morrison, MD
Steven Pergam, MD
Lisa Prosser, PhD

CDC Liaison
Rafael Harpaz, MD
Kathleen Dooling, MD

Terms of Reference of the Herpes Zoster Work Group

The objective of the Herpes Zoster Work Group is to develop evidence-informed vaccine policy for the use of herpes zoster vaccines. The Work Group will:

- Consider vaccine and programmatic performance of the currently licensed live attenuated vaccine (Zostavax, ZVL, Merck)
- Consider the efficacy, safety and duration of protection of the adjuvanted subunit vaccine (Shingrix, HZ/su, GSK) that is currently under FDA review
- Identify programmatic options for both vaccines that incorporate cost effectiveness analyses and impact on disease burden

Recent Work Group Activities

- 28 conference calls since August 2015
- Presentations by manufactures and researchers on:
 - Effectiveness
 - Safety
 - Immunogenicity
 - Cost effectiveness
 - Programmatic barriers
- Considered the body of evidence regarding both vaccines
- Identified key zoster vaccine policy questions and discussed options

Key Forthcoming Presentations and Data for the Work Group

- CDC cost effectiveness analysis
- GSK plans regarding program implementation
 - Vaccine price
 - Efforts to assure series completion for this 2-dose vaccine
 - Efforts to inform and prepare vaccine providers and patients regarding reactogenicity
 - Efforts to minimize disparities

Presentations to ACIP

■ October 2016

- Herpes zoster epidemiology & Zostavax performance and coverage
- Phase III efficacy study of HZ/su (ZOE-50 & ZOE-70)

■ Feb 2017

- Safety Summary of HZ/su
- GRADE of HZ/su
- Considerations for policy

■ June 2017

- Zostavax Phase IV studies-- Effectiveness
- Zostavax GRADE
- Immunogenicity of HZ/su in prior Zostavax recipients
- Cost effectiveness analysis summary
- Considerations for policy

■ October 2017

- Vote

Acknowledgements

- **ACIP Herpes Zoster Work Group:** Edward Belongia, Paula Agger, Robin Avery, Lynn Bahta, Al Benson, Paul Cieslak, Jeff Cohen, Jeff Curtis, Kathleen Dooling, Jeff Duchin, Mary Pat Friedlander, Sandra Fryhofer, Rafael Harpaz, Sam Katz, Jeff Kelman, Vicki Morrison, Kelly Moore, Mark Netoskie, Kathy Neuzil, Steve Pergam, Lisa Prosser, Bill Schaffner, Ken Schmader, Adam Welch
- **CDC + other contributors:** Jessica Allen, Carolyn Bridges, Amanda Cohn, Angela Guo, Theresa Harrington, Shainoor Ismail, David Kim, Jessica Leung, Adriana Lopez, Mona Marin, Karen Mason, Ismael Ortega-Sanchez, Manisha Patel, Aparna Ramakrishnan, Ray Strikas, Chengbin Wang, Richard Warrington